Kristof Cuppens
@k_cupp_
Followers
501
Following
9K
Media
34
Statuses
446
MD MSc - Thoracic Oncology, master in hospital and health care management Hasselt - Belgium 🇧🇪 - PhD candidate Amsterdam/Leiden - he/him 🌈
België
Joined November 2014
Extremely proud to announce that our NEOPREDICT-Lung study on neoadjuvant PD-1 and LAG-3 inhibition in resectable NSCLC is now online in @NatureMedicine . Without any doubt one the highlights of my career so far.
5
19
73
Phase III SAFFRON in EGFR+ NSCLC WITH MET-alteration post osi is still recruiting @JessaZiekenhuis @JessaWetenschap @GLW_UHasselt @Oncology_at_AZ.
🫁 #ASCO2025 In-Depth! Dr @k_cupp_ on SACHI :.✔️ Oral savolitinib + osi.✔️ PFS: 7–8 vs 4 mo vs chemo.✔️ Good tolerability.👀 Watch now #MediMix #NSCLC #EGFR #MET
0
0
0
And let’s not forget the proportion of patients that don’t even get to therapy due to inadequate testing for AGAs or have no access to appropriate treatments.
Real-world data on 1323 EGFR+ NSCLC pts on 1L osimertinib:. • Median OS: 28.6 mo.• High-risk pts:. - TP53: 25.7. - Brain mets: 24.3. - Liver mets: 19.3. - ECOG ≥2: 18.1. This isn’t good enough. Patients & families deserve more.
0
0
2
RT @g_mountzios: #ASCO25 After 30 years of failed trials, #tarlatamab changes SoC for our pts with relapsed #SCLC :. ✅ mOS: 13.6 vs 8.3 mon….
0
80
0
RT @StephenVLiu: #ASCO25 Dr. @charlesrudin presents interim analysis of DeLLphi-304: randomized phase II study of tarlatamab (DLL3 TCE) vs….
0
39
0
Another breakthrough for our SCLC patients! Based on personal experience, this regimen is well tolerated when properly managed. Proud that our site @JessaZiekenhuis has yet again significantly contributed to a practice changing study. @JessaWetenschap @GLW_UHasselt.
IMforte: RP3 maintenance lurbi+atezo ES-SCLC.CNS+ excluded. Enrolled post #4 chemo-atezo if non-PD. GCSF supported. PFS HR=0.5: 2.1 to 5.5mo.OS HR=0.73: 10.6 to 13.2mo (from randomztn).ORR 19.4 vs 10.4mo .AEs as expected. Bravo: a new standard of care #ASCO25
0
4
15
RT @DrSanjayPopat: IMforte: RP3 maintenance lurbi+atezo ES-SCLC.CNS+ excluded. Enrolled post #4 chemo-atezo if non-PD. GCSF supported. PFS….
0
10
0
RT @NReguart: 🔂The earlier the better?.🧪 Who needs more treatment?.🎯 How to improve cure? 👏👏👏👏 @HendriksLizza #ASCO25 .
0
9
0
RT @nicogirardcurie: More patients cured with neoadjuvant immunotherapy: CheckMate-816 OS now in #NEJM #ASCO2025
0
25
0
Results of Delphi-304 usher a new era for SCLC patients. Finally a truly game changer in the fight against this frightening disease. Immensely proud to have been part of this study. @ASCO @JessaZiekenhuis @JessaWetenschap @GLW_UHasselt @g_mountzios .
0
0
1
RT @g_mountzios: Being part of a history-making drug that helps pts with #SCLC live longer and better is the biggest reward a thoracic onco….
0
43
0
RT @JessaZiekenhuis: 🔬 Onze nieuwe CTC-website staat online! 💻 . Medisch-wetenschappelijk onderzoek is essentieel voor betere zorg. Het Jes….
0
1
0
RT @aftimosp: Now available in @Nature_NPJ Precision Oncology, results from the BALLETT molecular profiling study 🧬 🎯 using CGP & a nationa….
0
7
0
RT @jillfeldman4: Can we shift the narrative from 'shared decision-making' to 'informed decision-making' so that the focus is where it shou….
0
16
0
RT @FordePatrick: Great day for lung cancer care! Addition of just 3 cycles of nivolumab immunotherapy to standard neoadjuvant chemo leads….
0
49
0
Adds some spice to the discussion on the added value of prolonged IO post-operative.
Update on CheckMate 816 by press release: adding nivolumab to neoadjuvant chemotherapy for resectable NSCLC improves survival - already demonstrated improvement in pCR and EFS. Important landmark! Eager to see the data relative to perioperative benefit.
0
0
5